Drug Information

Drug General Information
Drug ID
D0K4RK
Former ID
DNCL003319
Drug Name
Blinatumomab
Synonyms
AMG 103
Drug Type
Monoclonal antibody
Indication Acute lymphoblastic leukemia [ICD9: 204.0, 556; ICD10:C91.0] Approved [889388], [889412]
Company
Amgen
CAS Number
CAS 853426-35-4
Target and Pathway
Target(s) B-lymphocyte antigen CD19 Target Info Modulator [533123]
T-cell surface glycoprotein CD3 Target Info Modulator [533123]
KEGG Pathway PI3K-Akt signaling pathway
Hematopoietic cell lineage
B cell receptor signaling pathway
Epstein-Barr virus infection
Primary immunodeficiency
NetPath Pathway IL-7 Signaling Pathway
PANTHER Pathway B cell activation
Pathway Interaction Database BCR signaling pathway
Reactome PIP3 activates AKT signaling
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
Constitutive Signaling by Aberrant PI3K in Cancer
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
WikiPathways Human Complement System
Signaling by the B Cell Receptor (BCR)
PIP3 activates AKT signaling
B Cell Receptor Signaling Pathway
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
References
Ref 889388ClinicalTrials.gov (NCT02013167) Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
Ref 889412ClinicalTrials.gov (NCT02393859) Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HR First Relapse B-precursor ALL
Ref 5331232014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.